• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/9/25 7:09:33 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    false 0001433607 0001433607 2025-05-09 2025-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT PURSUANT

    TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): May 9, 2025

     

    InspireMD, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction of Incorporation)

     

    001-35731   26-2123838

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    4 Menorat Hamaor St. Tel Aviv, Israel   6744832
    (Address of Principal Executive Offices)   (Zip Code)

     

    (888) 776-6804

    (Registrant’s Telephone Number, Including Area Code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   NSPR   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition

     

    On May 9, 2025, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the first quarter ended March 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    99.1   Press release, dated May 9, 2025 (furnished herewith pursuant to Item 2.02)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      INSPIREMD, INC.
         
    Date: May 9, 2025 By: /s/ Craig Shore
      Name: Craig Shore
      Title: Chief Financial Officer

     

     

     

    Get the next $NSPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InspireMD Reports First Quarter 2025 Financial Results

      MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launchContinued enrollment with excellent pace in the CGUARD

      5/9/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

      MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the Bank of America 2025 Healthcare Conference on Wednesday, May 14, 2025, at 1:15PM Eastern Time / 10:15AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the "News & Events" section of the company's website at: https://www.inspiremd.com/en/events/ About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by pro

      4/30/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Announce First Quarter 2025 Financial Results

      MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by

      4/25/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by InspireMD Inc.

      SC 13G - InspireMD, Inc. (0001433607) (Subject)

      12/4/24 4:31:06 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

      SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

      11/14/24 6:35:20 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

      SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

      10/28/24 4:02:11 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Financials

    Live finance-specific insights

    See more
    • InspireMD Reports First Quarter 2025 Financial Results

      MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launchContinued enrollment with excellent pace in the CGUARD

      5/9/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Announce First Quarter 2025 Financial Results

      MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by

      4/25/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

      MIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approvalAnnounced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use du

      3/12/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Tommasoli Andrea was granted 232,616 shares, increasing direct ownership by 47% to 727,694 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:33 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Director Berman Michael was granted 32,491 shares, increasing direct ownership by 14% to 264,533 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:18 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • CEO and President Slosman Marvin was granted 558,417 units of Restricted Stock Units, increasing direct ownership by 30% to 2,410,536 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:26 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    SEC Filings

    See more
    • InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - InspireMD, Inc. (0001433607) (Filer)

      5/9/25 7:09:33 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by InspireMD Inc.

      10-Q - InspireMD, Inc. (0001433607) (Filer)

      5/8/25 4:05:21 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by InspireMD Inc.

      DEFA14A - InspireMD, Inc. (0001433607) (Filer)

      4/16/25 4:05:25 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    See more
    • InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

      MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE:ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his

      11/25/24 4:05:00 PM ET
      $ABT
      $NSPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

      TEL AVIV, Israel and MIAMI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that the Company has appointed principal investigators (PIs) for its upcoming C-GUARDIANS II clinical trial of the SwitchGuard™ Neuroprotection System (NPS). Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, have enthusiastically agreed to act as lead PIs for the trial.

      2/12/24 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

      Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports inducement grant under NASDAQ listing rule 5635(c)(4) TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America. Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team. Marvin Slosman, Chief Executive Officer of InspireMD

      1/3/24 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Roubin Gary S bought $126,540 worth of shares (50,000 units at $2.53), increasing direct ownership by 13% to 438,902 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      12/4/23 4:15:25 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care